
    
      The goal of this study is to determine if preoperative dosing and sustained administration of
      pan-genotypic DAA therapy after cardiac transplantation prevents the transmission of
      hepatitis C virus (HCV) infection from an HCV-positive donor heart to an HCV na√Øve recipient.
    
  